# Table of Contents

Preface ................................................................. xv

Editorial Comments .............................................. xvii

About the Authors .................................................. xix

Section 1. Routine Tube Methods ............................... 1

1-A. ABO Grouping and RhD Typing ............................ 2
1-B. Testing for Unexpected Antibodies: LISS Additive Procedure .......................... 7
1-C. Crossmatching by LISS Antiglobulin ...................... 11
1-D. Weak D Testing Procedure .................................. 15
    Table 1-D-1. Interpretation Recommendations for Direct and Indirect Tests with Anti-D .......................... 20
1-E. Crossmatching by Immediate-Spin ........................ 21
1-F. Grading and Scoring Serologic Reactions ................ 25
    Table 1-F-1. Grading Serologic Reactions .................. 28
1-G. Intralaboratory Competency Testing: IAT Reading and Grading Procedure .......... 29

Section 2. Antibody Detection ................................... 37

2-A. Testing by Albumin Addition/Layering .................... 38
2-B. Testing by Albumin Antiglobulin ........................... 41
2-C. Testing by Enzyme IAT ...................................... 45
2-D. Testing by LIP IAT ........................................... 50
2-E. Testing by LISS Wash IAT ................................... 55
2-F. Testing by LISS-Ficin IAT ................................... 59
2-G. Testing by Polyethylene Glycol IAT ......................... 64
2-H. Testing for Cold-Reactive Antibodies by Direct Agglutination ....................... 68
2-I. Testing by Saline IAT ........................................ 71

Section 3. Enzyme Techniques ................................... 75

3-A. Detecting Antibodies with the Bromelain One-Stage Method .......................... 77
3-B. Treating Red Cells with \( \alpha \)-Chymotrypsin ................... 80
### Section 3. Methods for Detecting and Treating Antibodies

<table>
<thead>
<tr>
<th>Subsection</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-C. Detecting Antibodies with the Ficin One-Stage Method</td>
<td>83</td>
</tr>
<tr>
<td>3-D. Treating Red Cells with Ficin</td>
<td>86</td>
</tr>
<tr>
<td>3-E. Treating Red Cells with Neuraminidase (T-Activation)</td>
<td>90</td>
</tr>
<tr>
<td>3-F. Detecting Antibodies with the Papain One-Stage Method</td>
<td>93</td>
</tr>
<tr>
<td>3-G. Treating Red Cells with Papain</td>
<td>96</td>
</tr>
<tr>
<td>3-H. Treating Red Cells with Pronase</td>
<td>100</td>
</tr>
<tr>
<td>3-I. Treating Red Cells with Trypsin (Crude Enzyme)</td>
<td>104</td>
</tr>
<tr>
<td>3-J. Treating Red Cells with Trypsin (Purified Enzyme)</td>
<td>108</td>
</tr>
<tr>
<td>3-K. Treating Red Cells with ZZAP</td>
<td>112</td>
</tr>
</tbody>
</table>

### Section 4. Elution Techniques

<table>
<thead>
<tr>
<th>Subsection</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4-A. Washing Before Eluting</td>
<td>116</td>
</tr>
<tr>
<td>4-B. Eluting Antibodies with Chloroform</td>
<td>118</td>
</tr>
<tr>
<td>4-C. Eluting Antibodies with Chloroform/Trichloroethylene</td>
<td>122</td>
</tr>
<tr>
<td>4-D. Eluting Antibodies with Citric Acid</td>
<td>126</td>
</tr>
<tr>
<td>4-E. Eluting Antibodies with Cold Glycine Acid</td>
<td>130</td>
</tr>
<tr>
<td>4-F. Eluting Antibodies from Stroma</td>
<td>134</td>
</tr>
<tr>
<td>4-G. Eluting Antibodies with Ether</td>
<td>138</td>
</tr>
<tr>
<td>4-H. Eluting Antibodies by Freezing-Thawing (Lui Method)</td>
<td>142</td>
</tr>
<tr>
<td>4-I. Eluting Antibodies by Freezing-Thawing (Wiener Method)</td>
<td>145</td>
</tr>
<tr>
<td>4-J. Eluting Antibodies by Heat</td>
<td>149</td>
</tr>
<tr>
<td>4-K. Eluting Antibodies with Methylene Chloride</td>
<td>152</td>
</tr>
<tr>
<td>4-L. Eluting Antibodies with Microwaves</td>
<td>156</td>
</tr>
<tr>
<td>4-M. Eluting Antibodies from Placental Tissue</td>
<td>159</td>
</tr>
<tr>
<td>4-N. Eluting Antibodies Using Ultrasound</td>
<td>162</td>
</tr>
<tr>
<td>4-O. Eluting Antibodies with Xylene/D-Limonene</td>
<td>165</td>
</tr>
<tr>
<td>4-P. Dissociating IgG from Cells Using EDTA-Glycine-HCl</td>
<td>169</td>
</tr>
<tr>
<td>4-Q. Dissociating IgG from Cells Using Chloroquine Diphosphate</td>
<td>172</td>
</tr>
</tbody>
</table>

### Section 5. Cell Separation Methods

<table>
<thead>
<tr>
<th>Subsection</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-A. Harvesting Autologous Red Cells by Direct Centrifugation</td>
<td>176</td>
</tr>
<tr>
<td>5-B. Harvesting Autologous Red Cells Using Phthalate Esters</td>
<td>179</td>
</tr>
<tr>
<td>5-C. Cell Separation Using Percoll Procedure</td>
<td>183</td>
</tr>
</tbody>
</table>
Table of Contents

5-D. Harvesting Autologous Red Cells in Hemoglobin S or Sickle Cell Disease 186
5-E. Separating Mixed-Cell Populations with Antibodies 189
5-F. Mononuclear Cell Separation Procedure 192

Section 6. Alternative Serologic Methods for Antibody Detection 195

6-A. Gel: Preparing Buffered Gel Columns 197
6-B. Gel: Preparing Anti-IgG Columns 201
6-C. Gel: Detecting Antibodies Using Buffered Gel Columns 205
6-D. Gel: Detecting Antibodies Using Anti-IgG Columns 208
6-E. Gel: Adapting Prefilled Neutral Buffer Columns for Use with Murine IgG Antibodies 211
6-F. Gel: Adapting Prefilled Anti-IgG Columns for Use in a Modified PEG-IAT 215
6-G. Microplate: ABO Grouping and RhD Typing Procedure 219
6-H. Microplate: Antibody Detection Using LISS Procedure 225
6-I. Microplate: LIP Technique Procedure 229
6-J. Capillary: Saline Agglutination Procedure 232
6-K. Capillary: Albumin One-Layer Procedure 235
6-L. Capillary: Albumin Two-Layer Procedure 238
6-M. Capillary: Papain One-Stage Procedure 241
6-N. Capillary: Ficin One-Stage Procedure 244
6-O. Capillary: IAT on Precoated Red Cells Procedure 247
6-P. Capillary: Precoating for IAT Procedure 250
Appendix 6-1. Sephadex Gel Beads: Background Information 253
Appendix 6-2. Agglutination Reactions in Gel Columns 254
Appendix 6-3. Microplate Tests: General Considerations 255
Appendix 6-4. Capillary Methods: General Considerations 257

Section 7. Reagent Red Cells (Non-Enzyme-Treated) 259

7-A. Preparing C3b/C4b-Coated Red Cells 261
7-B. Preparing C3b/C4b-Coated Red Cells with Table Sugar 264
7-C. Preparing IgM/C3b-Coated Red Cells 267
7-D. Preparing C3b-Coated Red Cells: Fruitstone Method 271
7-E. Preparing C4b-Coated Red Cells 274
7-F. Preparing IgA- and IgM-Coated Red Cells 277
7-G. Preparing IgG-Coated Red Cells ................................................................. 281
7-H. Treating Red Cells: AET Procedure ............................................................. 285
7-I. Treating Red Cells: 0.2 M DTT Procedure ..................................................... 287
7-J. Inactivating S Antigen: Sodium Hypochlorite Treatment ............................. 289
7-K. Freezing Red Cells: Glycerol Preservation and Recovery ............................ 291
7-L. Freezing Red Cells: Liquid-Nitrogen Preservation and Recovery .................... 294

Section 8. Antibody Identification ........................................................................... 299
8-A. Identification of Single or Multiple Antibodies .............................................. 300
   Figure 8-A-1. Considerations in investigating unexpected antibodies ............... 304
   Figure 8-A-2. Considerations in investigating blood samples with a positive autocontrol ................................................................. 305
   Table 8-A-1. Serologic Characteristics of Some Alloantibodies to Red Cell Antigens ................................................................. 306
8-B. Management of Samples and Patients with Cold Agglutinins ......................... 309
8-C. Evaluation of Panel Results: Crossing Out ..................................................... 313
   Figure 8-C-1. Antigens crossed out on each individual panel cell ....................... 315
   Figure 8-C-2. Antigens crossed out on the top of the antigen profile .................. 315
8-D. Selected Cells Process ....................................................................................... 316
8-E. Selection of Antigen-Negative Blood for Transfusion ..................................... 319
   Table 8-E-1. Selection of Antigen-Negative Blood for Transfusion: Some Examples of Commonly Encountered Antibodies ............... 323
8-F. Determination of Probability Levels ............................................................... 324
   Table 8-F-1. Probability Values. .......................................................................... 328
8-G. Acidifying Sera ................................................................................................. 329
8-H. Using a Combined Adsorption/Elution Procedure .......................................... 331
8-I. Detecting Trypsin-Resistant N_{VG} Receptors .............................................. 335
8-J. Using Soluble Blood Group Substances in an Inhibition Procedure ................ 338
   Table 8-J-1. Antibody Inhibition by Blood Group Substances ............................ 341
8-K. Inhibiting Rouleaux with DIDS ..................................................................... 342
8-L. Identifying Anti-N_{form} ................................................................................. 345
8-M. Detecting Complement-Fixing Antibodies by a Two-Stage EDTA-IAT ............ 348
   Appendix 8-1. Evaluation of Initial Antibody Identification Panel ..................... 351
   Appendix 8-2. Approaches to Identify/Confirm Antibody Specificity .................. 352
Table of Contents

Section 9. Investigating Antibodies to High-Prevalence Antigens .......................... 353
  Table 9-1. Effect of Papain/Ficin and Thiol Reagents on Reactions of Antibodies to High-Prevalence Red Cell Antigens .......................... 357
  Table 9-2. Effects of Enzymes and Chemicals on Reactions of Antibodies to High-Prevalence Red Cell Antigens .......................... 358
  Figure 9-1. Investigation of antibodies to high-prevalence antigens ............... 359
  9-A. Inhibiting Antibodies with Pooled Plasma or Serum .......................... 360
  9-B. Identifying Anti-Ch/Rg: Rapid Procedure ........................................ 363
  9-C. Recognizing Antibodies to HLA Determinants ................................ 366
  9-D. Using Allogeneic C4 for Adsorption of Anti-Ch/Rg .......................... 369
  9-E. Using 2 M Urea for the Screening/Confirmation of Jk(a–b–) Red Cells .... 372

Section 10. Prenatal and Perinatal Testing .................................................. 375
  10-A. Tests During Pregnancy ............................................................. 381
  10-B. Rh Immune Globulin Administration ............................................ 384
    Figure 10-B-1. Flow diagram for Rh Immune Globulin administration ......... 388
  10-C. Evaluation of Hemolytic Disease of the Fetus and Newborn at Delivery .... 389
  10-D. Prenatal Antibody Titration Procedure ....................................... 392
  10-E. Differentiating Anti-G from Anti-C + Anti-D by Adsorption/Elution ........ 397
  10-F. Screening for Fetal RhD-Positive Red Cells in Maternal RhD-Negative Samples .......................................................... 401
  10-G. Quantifying Anti-D with the Enzyme-Linked Antiglobulin Test .............. 405
  10-H. Screening for Large Fetomaternal Hemorrhage (Modified Kleihauer-Betke Acid-Elution Test) .................................................. 410
  10-I. Quantifying Fetomaternal Hemorrhage with the Enzyme-Linked Antiglobulin Test .......................................................... 414
  10-J. Analyzing Amniotic Fluid by Spectrophotometry ................................ 419
  10-K. Treating Cord Blood Contaminated with Wharton’s Jelly .................... 423

Section 11. Investigating Samples Containing Autoantibodies ............................ 425
  Table 11-1. Specificity of Cold-Reactive Autoantibodies: Comparison of Reactions with Untreated O, I+ Red Cells ................................ 429
  11-A. Investigation of Cases of Immune Hemolysis and/or a Positive DAT .......... 430
  11-B. Antiglobulin Testing: Direct Tests with Anti-IgG and Anti-C3 (Test Tube Method) .......................................................... 436
11-C. Antiglobulin Testing: Direct Tests with Anti-IgM and Anti-IgA (Test Tube Method) .................................................. 440
11-D. Antiglobulin Testing: Direct Tests with Anti-IgM and Anti-IgA (Column Agglutination Test) ........................................ 443
11-E. Antiglobulin Testing: Direct Tests with Polyclones ........................................................... 446
11-F. Antiglobulin Testing: Enzyme-Linked DAT ................................................................. 450
11-G. Dispersing Autoagglutination .................................................................................... 454
11-H. Testing the Thermal Amplitude of a Cold-Reactive Autoantibody. ............................... 456
11-I. Diagnostic Testing of a Cold-Reactive Autoantibody by Titration (Overnight Method) ......................................................... 459
11-J. Testing of a Cold-Reactive Autoantibody by Titration ................................................. 462
11-K. Determining Specificity of a Cold-Reactive Autoantibody by Titration ....................... 465
11-L. Adsorbing Cold-Reactive Autoantibodies with Autologous Red Cells ....................... 468
11-M. Adsorbing Cold Autoantibodies with Heterologous (Rabbit) Red Cells .................... 471
11-N. Testing for PCH Using the Donath-Landsteiner Test .................................................... 475
11-O. Determining the Relative RH Specificity of Warm-Reactive Autoantibodies by Titration .................................................................................................................. 478
11-P. Adsorbing Warm-Reactive Autoantibodies with Enzyme-Treated Autologous Red Cells ................................................................................................................ 481
11-Q. Adsorbing Autoantibodies with ZZAP-Treated Autologous Red Cells ...................... 485
11-R. Adsorbing Autoantibodies with ZZAP-Treated Autologous Red Cells (Micromethod) ................................................................................................................ 489
11-S. Adsorbing Warm-Reactive Autoantibodies with Allogeneic Red Cells ....................... 493
11-T. Evaluating Alloadsorbed Serum Results: Crossing Out ................................................ 497
11-U. Prewarming Indirect Antiglobulin Testing ................................................................... 503

Section 12. Investigating Drug-Induced Hemolysis ......................................................... 507
   Table 12-1. Drugs Reported to Cause Immune Hemolysis and a Positive DAT ................. 510
12-A. Dissolving Drugs in Solution ..................................................................................... 515
12-B. Preparing Urine for Detecting Metabolite-Dependent Antibodies ............................. 522
12-C. Detecting Drug-Dependent Antibodies Reacting with Drug-Treated Red Cells ........ 525
12-D. Detecting Antibodies to Semisynthetic Penicillins ...................................................... 531
12-E. Detecting Cephalothin-Dependent Antibodies .......................................................... 535
12-F. Detecting Drug-Dependent Antibodies Reacting in the Presence of Drug ................. 538
12-G. Detecting Metabolite-Dependent Antibodies Reacting in the Presence of Drug ......... 545
Table of Contents

Section 13. Investigating ABO Grouping Problems ................................................. 551
  Table 13-1. Causes of ABO Grouping Discrepancies ............................................. 558
  Table 13-2. Some Anomalous or Uncommon ABO Grouping Results ......................... 559
  Figure 13-1. Flow chart for the investigation of ABO discrepancies ....................... 560
  13-A. Investigation of Mixed-Field Reactions ..................................................... 561
  13-B. Investigation of Nonconcordant ABO Grouping Reactions .............................. 563
  13-C. Evaluating an ABO Discrepancy .............................................................. 567
  13-D. Using Protease-Treated Red Cells for ABO Grouping Resolution ..................... 571
  13-E. Confirming Weak A or B Antigen Expression by Adsorption and Heat Elution .... 573
  13-F. Confirming Weak A or B Antigen Expression by Adsorption and Freezing-Thawing (Lui) Elution .......................................................... 577
  13-G. Detecting Minor Red Cell Populations and ABO Mixtures ............................. 581
  13-H. Determining ABH Secretor Status ............................................................. 584
  13-I. Determining H Antigen Expression ............................................................ 587
  13-J. Separating A:O Mixtures ............................................................................. 590
  13-K. Detecting A and B Transferases by Conversion of Group O Red Cells ............. 594
  13-L. Prewarming ABO Reverse Grouping ............................................................ 597
  13-M. Selecting Plasma Containing High-Titer Anti-A and/or Anti-B ....................... 600

Section 14. Investigating Red Cell Polyagglutination ............................................. 603
  Table 14-1. Reactions of Polyagglutinable Red Cells with Lectins ......................... 604
  14-A. Detecting Polyagglutination with AB and Cord Blood Serum ......................... 605
  14-B. Preparing Crude Extracts of Lectins ......................................................... 608
  14-C. Preparing Crude Extracts of Salvia Lectins ............................................... 612
  14-D. Preparing Solutions of Purified Lectins ..................................................... 616
  14-E. Aggregating Red Cells with Polybrene ....................................................... 619
  14-F. Acetyling Red Cells .................................................................................. 622
  14-G. Inhibiting Acquired-B Reactivity ............................................................... 626
  14-H. Testing Red Cells with Acidified Anti-B .................................................... 629

Section 15. Miscellaneous Methods ................................................................. 631
  15-A. Testing for PNH: Acid Hemolysis (Ham’s) Test ....................................... 632
  Table 15-A-1. Acid Hemolysis Test Procedure ................................................. 635
  15-B. Testing for HEMPAS: Modified Acid Hemolysis (Ham’s) Test ...................... 636
15-C. Converting IgG Antibodies to Direct Agglutinins. ........................................... 639
15-D. Assessing Red Cell Survival Using $^{51}$Cr-Labeled Red Cells ......................... 642
15-E. Differentiating IgM from IgG Antibodies Using 0.01 M DTT ............................. 647
Table 15-E-1. Interpretation of 2-ME/DTT Studies to Determine Immunoglobulin Class of Antibody .................................................. 650
15-F. Differentiating IgM from IgG Antibodies Using 2-ME ...................................... 651
15-G. Performing Dosage Studies Using the Enzyme-Linked Antiglobulin Test ............. 655
15-H. Predicting Clinical Significance Using the Monocyte Monolayer Assay ............... 660
15-I. Screening for PNH: Sucrose Hemolysis Test .................................................. 665
15-J. Converting Plasma to Serum ................................................................. 668
15-K. Isolating Genomic DNA from Peripheral Blood ........................................... 671
15-L. Amplifying Genomic DNA Using a Hot Start Taq PCR ................................. 674
15-M. Preparing and Running an Agarose Gel for Analysis of PCR Products ............. 679

Appendices ............................................................................................................. 683

Appendix A. Reagent Preparation and Storage .................................................. 684
Appendix B. Reagent Preparation Documentation Form ..................................... 703

Index ..................................................................................................................... 705